We recently compiled a list of the 10 Most Profitable Cheap Stocks to Buy Now. In this article, we are going to take a look ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future medicines to market.

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...